US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.88

+0.63001.69%

Post-market: 37.880.00000.00%19:30 EDT

Volume:52.02K

Turnover:1.97M

Market Cap:342.44M

PE:- -

High:37.97

Open:37.82

Low:37.60

Close:37.25

52wk High:39.80

52wk Low:30.66

Shares:9.04M

Float Shares:9.04M

Volume Ratio:0.80

T/O Rate:0.58%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

Imugene Reports 81% Overall Response Rate in Azer-Cel Phase 1b Study, Shares Surge 22%

MT Newswires Live

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Kura Oncology Reports First Quarter 2026 Financial Results

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

Press Release: Immatics Announces First Quarter 2026 Financial Results and Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/ORR/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.88,"timestamp":1790971200000,"preClose":37.25,"halted":0,"volume":52018,"hourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016912751677852417,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"Market Closed","change":0.63,"latestTime":"10-02 16:00:00 EDT","open":37.82,"high":37.9699,"low":37.6,"amount":1965631.8915940002,"amplitude":0.00993,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":37.25,"sharesOutstanding":12900000,"nav":37.48,"aum":338819200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.798571665918667,"impliedVol":0.202,"impliedVolPercentile":0.7043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9040000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.798571665918667,"shares":9040000,"dividePrice":0,"high":37.9699,"amplitude":0.00993,"preClose":37.25,"low":37.6,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":37.88,"eps":0,"divideRate":0,"volume":52018,"delay":0,"ttmEps":0,"open":37.82,"prevYearClose":34.16,"prevWeekClose":38.3781,"prevMonthClose":37.77,"prevQuarterClose":37.77,"fiveDayClose":38.3781,"twentyDayClose":39.1754,"sixtyDayClose":36.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639569988","title":"Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639569988","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639569988?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228800,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., May  31, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today pres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303918/0/en/Replimune-Presents-Final-First-in-Human-Data-for-RP2-in-Advanced-Solid-Tumors-During-Oral-Presentation-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","BK4157","AFG","IE00B7SZL793.SGD","AEIS","LU0757428866.USD","MAGE","REPL","IE00B19Z4B17.USD","BK4107","IE00B66KJ199.SGD","BK4139","LU1815336091.USD","IE0031619046.USD","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639048566","title":"Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2639048566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639048566?lang=en_us&edition=fundamental","pubTime":"2026-05-31 02:30","pubTimestamp":1780165800,"startTime":"0","endTime":"0","summary":"TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303899/0/en/Eikon-Therapeutics-Presents-Data-on-Clinical-Stage-Programs-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","BK4187","BK4585","IE0031619046.USD","LU2487616109.SGD","LU2065731478.USD","BK4107","SSI","IE00B7SZL793.SGD","BK4588","ORR","AFG","L","LU0210528500.USD","CRS","LU0053666078.USD","IE00B66KJ199.SGD","BK4006","BK4139","EIKN","BK4117","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601202","title":"Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601202","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639601202?lang=en_us&edition=fundamental","pubTime":"2026-05-31 02:15","pubTimestamp":1780164900,"startTime":"0","endTime":"0","summary":"First investigational PD-(L)1xVEGF bispecific immunomodulator to present global datashowingencouraging efficacyin combination with chemotherapyinfirst-linenon-small cell lung canceracrossPD-L1expressi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303897/0/en/Global-Data-for-BioNTech-and-Bristol-Myers-Squibb-s-PD-L1xVEGF-A-Bispecific-Pumitamig-Shows-Encouraging-Efficacy-in-Patients-with-Non-Small-Cell-Lung-Cancer-in-ROSETTA-Lung-02-Tria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","LU1868836914.USD","LU1868837136.USD","LU1868837300.USD","BK4023","LU0267386448.USD","BK4534","LU1883839398.USD","BK4581","L","BK4559","LU1571399168.USD","LU0210528500.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","PD","LU1430594728.SGD","LU0061475181.USD","BK4107","LU0225284248.USD","BMS","IE0002141913.USD","LU0096364046.USD","LU0225771236.USD","LU1670710661.SGD","LU0868494617.USD","LU1670711040.USD","LU0985481810.HKD","BK4211","LU1093756325.SGD","LU0306806265.USD","BK4195","IE00B2B36J28.USD","LU2360032135.SGD","LU1868836591.USD","BK4532","ORR","PFS","LU0114720955.EUR","LU1868836757.USD","LU0882574055.USD","LU2242652126.USD","BMY","IE00BSNM7G36.USD","LU1261432733.SGD","IE00BFXG1179.USD","LU0321505439.SGD","LU1093756168.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609563","title":"Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609563","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639609563?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:00","pubTimestamp":1780142400,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., May  30, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today pres","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303875/0/en/Replimune-Presents-3-Year-Landmark-Overall-Survival-Analysis-from-IGNYTE-Clinical-Trial-During-Oral-Presentation-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","REPL","BK4107","LARK","BK4211","BK4117","BK4139","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639095506","title":"Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639095506","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639095506?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:00","pubTimestamp":1780142400,"startTime":"0","endTime":"0","summary":"One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303876/0/en/Immatics-Presents-Clinical-Activity-of-IMA203CD8-PRAME-Cell-Therapy-in-Hard-to-Treat-Gynecologic-Cancers-at-2026-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","CRS","BK4006","LU2065731478.USD","BK4187","IE00B19Z4B17.USD","LU0963586101.USD","IMTX","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638513461","title":"Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2638513461","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638513461?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:02","pubTimestamp":1779789720,"startTime":"0","endTime":"0","summary":"– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-nave CRC pati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300885/35186/en/Kura-Oncology-Reports-Strong-Clinical-Activity-and-Safety-with-Darlifarnib-Adagrasib-in-KRAS-G12C-Mutated-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0300736492.USD","BK4139","KURA","BK4213","LU2236285917.USD","LU0266512127.USD","LU0053671581.USD","BK4179","CRC","LU2456880835.USD","ORR","LU1804176565.USD","LU2265009873.SGD","BK4505","LU2417539215.USD","LU0054578231.USD","LU0456854461.SGD","FTI","LU0300736062.USD","IE00BD6J9T35.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637116373","title":"2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2637116373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637116373?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:00","pubTimestamp":1779451200,"startTime":"0","endTime":"0","summary":"BEIJING, May  22, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300080/0/en/2026-ASCO-Pivotal-Data-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PB","CR","BK4211","IE00BLDYK493.USD","TLS","IE00B64QTZ34.USD","BK4195","BK4097","PFS","ORR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637645073","title":"Imugene  Reports 81% Overall Response Rate in Azer-Cel Phase 1b Study, Shares Surge 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637645073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637645073?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:35","pubTimestamp":1779417331,"startTime":"0","endTime":"0","summary":"Imugene  said data from its azer-cel Phase 1b abstract, published on the American Society of Clinical Oncology  website, showed an overall response rate  of 81% among 16 evaluable patients, according to a Friday Australian bourse filing.The company said Azer-cel, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 to treat blood cancers, showed responses across multiple lymphoma and leukemia subtypes, including a 60% response rate in diffuse large B-cell lymphoma  and a 100% response rate in marginal zone lymphoma .The company's shares rose 22% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","ORR","IMU.AU","BK7067","ORR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365900","title":"Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365900","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637365900?lang=en_us&edition=fundamental","pubTime":"2026-05-22 08:00","pubTimestamp":1779408000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  21, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3299861/0/en/Ascentage-Pharma-Releases-Latest-Clinical-Data-from-Multiple-Trials-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWS","NB","BK4023","BK4139","BK4211","CR","LU1169590202.USD","PD","LU1169589451.USD","BK4168","BK4195","ORR","PFS","AAPG","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357750","title":"Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357750","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357750?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:39","pubTimestamp":1779399540,"startTime":"0","endTime":"0","summary":"In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299814/0/en/Zentalis-Pharmaceuticals-to-Present-Phase-1b-MUIR-Trial-Data-Showing-Encouraging-Clinical-Activity-and-Manageable-Safety-Profile-of-Azenosertib-Plus-Paclitaxel-in-Platinum-Resistan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","ORR","BK4211","PROC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357754","title":"Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357754","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357754?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:30","pubTimestamp":1779399000,"startTime":"0","endTime":"0","summary":"ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multip","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299810/0/en/Crescent-Biopharma-Announces-Trial-in-Progress-Presentation-for-ASCEND-Study-of-CR-001-a-PD-1-x-VEGF-Bispecific-Antibody-at-Upcoming-American-Society-of-Clinical-Oncology-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","PRGS","LU1169589451.USD","BK4117","PD","BK4097","LU1169590202.USD","BK4195","ORR","AFG","BK4107","BK4023","LU2065732104.USD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637211382","title":"Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2637211382","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637211382?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:28","pubTimestamp":1779359280,"startTime":"0","endTime":"0","summary":"SHANGHAI, May  21, 2026  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299131/0/en/Junshi-Biosciences-Announces-Approval-of-Toripalimab-NDA-for-the-1st-line-treatment-of-HER2-Expressing-Urothelial-Carcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HR","RCC","HCC","BK4203","BK4006","ORR","BK4225"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725578","title":"Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725578","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725578?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:10","pubTimestamp":1778789400,"startTime":"0","endTime":"0","summary":"Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295384/0/en/Cardiff-Oncology-Reports-First-Quarter-2026-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","PFS","BK4195","BK4211","CEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746529","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635746529?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:47","pubTimestamp":1778770020,"startTime":"0","endTime":"0","summary":"-- Updated positive data from iadademstat in 1L AML unfit patients to be. presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract. -- Ongoing broad expansion of iadademstat clinical development across. PORTICO-2 Phase III trial with vafidemstat in aggression in BPD. -- Strong cash position at the quarter ended March 2026: $25.4 million. \"The iadademstat development platform continues to expand, reinforcing its potential as a high-value hematology and oncology asset,\" Dr. Buesa continued. \"Enrollment is advancing across multiple investigator-sponsored studies at leading U.S. cancer centers and National Cancer Institute-sponsored trials in hematologic malignancies and solid tumors. At the same time, em","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4081","PTA","BK4590","ORR","BK4561","BK4144","BK4588","EMA","SCD","BK4581","BK4585","NCI","ET","BK4202","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786966","title":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786966?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May  13, 2026  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293836/37149/en/PDS-Biotech-Reports-First-Quarter-2026-Financial-Results-and-Provides-Clinical-Programs-and-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4588","BK4195","PFS","ORR","BK4231","PDS","BK4211","BK4581","BK4585","BK4080","BK4092","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223869","title":"Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223869?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619780,"startTime":"0","endTime":"0","summary":"-- Announced encouraging preliminary safety and efficacy data across all. -- Announced publication in Cancer Discovery highlighting preclinical data. demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor. -- Clinical readouts expected in the second half of 2026 across all three. -- Cash runway expected to fund operations into 2028. SOUTH SAN FRANCISCO, Calif., May 12, 2026  -- BridgeBio Oncology Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.BBOT's portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition of KRAS in both its ON and OFF states, pan-KRAS coverage across major KRAS mutations, and disruption of RAS-driven PI3K<ALPHA> activation. Together, these assets uniquely position BBOT to achieve safe, concurrent, high-level suppressi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD6J9T35.USD","BK4097","IE00BZ199S13.USD","BK4512","LU2357305700.SGD","LU1720051017.SGD","BK4141","ON","LU1720051108.HKD","LU0266512127.USD","BK4605","IE00BFMHRM44.USD","LU1978683503.SGD","BK4195","LU0124384867.USD","LU1854104046.USD","LU1861214812.USD","LU0724618433.USD","LU1861219969.SGD","BBOT","LU0456854461.SGD","LU2298322129.HKD","BK4585","LU1861215975.USD","BK4213","LU1861220033.SGD","PRGS","BK4588","PR","ORR","LU1548497426.USD","BK4139","PFS","LU0348723411.USD","LU1854103824.USD","BK4211","CRC","LU2360107325.USD","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240536","title":"Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240536","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240536?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trialsDENALI Phase 2 tria","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293397/0/en/Zentalis-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Clinical-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4195","BK4080","PFS","ORR","BK4097","PRGS","ADC","BK4211","PROC","LU2065732104.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242093","title":"Kura Oncology Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242093","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242093?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616120,"startTime":"0","endTime":"0","summary":"– $5.8 million in KOMZIFTI (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and comb","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293355/35186/en/Kura-Oncology-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4505","BK4139","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219035","title":"PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219035?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human reza","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292786/0/en/PMV-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4183","ORR","IE0009354923.USD","PMVP","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634451218","title":"Press Release: Immatics Announces First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634451218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634451218?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583600,"startTime":"0","endTime":"0","summary":"-- SUPRAME Phase 3 interim and final analysis for PRAME cell therapy,anzu-cel, expected to be triggered in 2026, advancing toward the. -- Multiple key clinical data sets expected in 2026 across the portfolio,including four clinical-stage cell therapy and bispecific candidates. targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and. uterine), head and neck cancer, and other solid tumor indications. -- Phase 1 data readout with second-generation PRAME cell therapy,IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on. -- Phase 1b clinical data from PRAME bispecific, IMA402, as monotherapy and. initial data in combination with an immune checkpoint inhibitor at RP2D. bispecifics, IMA402 targeting PRAME and IMA401 targeting MAGEA4/8 in. -- Cash and cash equivalents as well as other financial assets of $521.5. million1  as of March 31, 2026; cash reach projected. Anzu-cel , previously called IMA203, is Immatics' lead PRAME cell therapy and is expected to be the C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","PFS","BK4195","BK4211","IMTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":118,"code":"91000000","status":"200"}]}}